Fierce Pharma March 4, 2024
Zoey Becker

After the U.S. government last month floated its first offers for 10 drugs on Medicare as part of the negotiations process laid out in the Inflation Reduction Act (IRA), the pricing talks are now in full swing.

Every drugmaker with a product on the list has responded to the government’s Feb. 1 pricing offer with a counteroffer, the Department of Health and Human Services (HHS) said in a Monday press release.

The agency is pleased with the “good-faith, up front negotiations,” HHS Secretary Xavier Becerra said in the release. “We are committed to constructive dialogue and are glad the drug companies are coming to the table.”

The industry, for its part, has routinely voiced complaints about a “lack of transparency”...

Today's Sponsors


Today's Sponsor


Topics: Biotechnology, CMS, Govt Agencies, HHS, Insurance, Medicare, Pharma, Pharma / Biotech
Biopharma M&A more than doubled in the first quarter compared to the year prior: report
23andMe: What If …
Bruker brokers $392M deal for frayed NanoString
Pharma Pulse 4/18/24: Is it Fair Certain Biotech Investors Get an Early Look? The Health and Healthcare of Millennials & more
Pharmacies Should Adopt Proactive Health, Wellness to Help Patients

Share This Article